

**TREATMENT FAILURE AND ASSOCIATED FACTORS AMONG INDIVIDUALS ON
SECOND LINE ANTIRETROVIRAL THERAPY ATTENDING MBALE REGIONAL
REFERRAL HOSPITAL: A RETROSPECTIVE COHORT STUDY**

SAM MATEKHA

REG NO: BU/GS16/MPH/9

**Supervisors: 1) Assoc Prof. Jayne Byakika-Tusiime
 2) Dr. John Peter Masette Masaba**

**A DISSERTATION SUBMITTED TO BUSITEMA UNIVERSITY DEPARTMENT OF
PUBLIC HEALTH IN PARTIAL FULFILLMENT OF THE REQUIREMENTS**

FOR THE AWARD OF A MASTER OF PUBLIC HEALTH

DEGREE OF BUSITEMA UNIVERSITY

December, 2020

Table of Contents

Contents

List of Tables	iv
List of Figures	v
Declaration	vi
Dedication	vii
Acknowledgement	viii
Dissertation Approval	ix
Acronyms and Abbreviations	x
Operational Definitions	x
ABSTRACT	xii
CHAPTER 1: INTRODUCTION AND BACKGROUND	1
1.1 Background	1
1.2 Statement of the Problem	5
1.3 Justification	6
1.4 General Objective	7
1.5 Specific Objectives	7
1.7 Conceptual Framework	8
CHAPTER 2: LITERATURE REVIEW	10
2.1 HIV Infection and Transmission	10
2.2 Antiretroviral Treatment	11
2.3 Treatment Outcomes among Individuals on Second line ART regimen	12
a) Clinical Outcomes	12
b) Immunologic Outcomes	13
c) Virologic Outcomes	14
d) Mortality while on Second line Regimen	15
2.4 Factors Contributing to ART Treatment Failure	16

a) Socio-demographic parameters and adherence.....	16
b) Baseline Laboratory and Clinical Parameters	18
c) Regimen Potency	19
d) Prescribing Practice and Pharmacokinetics	19
e) Health System related Factors	20
CHAPTER 3: MATERIALS AND METHODS	21
3.1 Study Design.....	21
3.2 Study Setting.....	21
3.3 Study Population.....	22
3.3.1 Target Population.....	22
3.3.2 Study Population.....	22
3.4 Sample Size.....	22
3.5 Study Variables.....	23
3.5.1 Dependent Variable	23
3.5.2 Independent Variables	23
3.6 Data Collection	24
3.7 Data Management	24
3.8 Data Analysis	24
3.9 Ethical Considerations	25
3.10 Plan for Dissemination of findings	26
Chapter 4: RESULTS	26
4.1 Socio-demographic Characteristics of Patients	26
4.2 Medical related Factors at ART initiation	27
4.3 Objective one: Cumulative Incidence of Treatment Failure.....	28
4.4 Objective two: The Mortality Rate of Individuals on Second line ART in MRRH	28
4.5 Objective three: The Factors Associated with Treatment Failure among Individuals on Second line ART Regimen in MRRH	31
4.5.1 Bivariate Analysis of Treatment Failure and Risk Factors.....	31
4.5.2 Multivariable Analysis of Treatment Failure and the Risk factors.....	33
CHAPTER 5: DISCUSSION.....	35

5.1 Introduction.....	35
5.2 Discussion.....	36
5.2.1 Cumulative Incidence of Treatment Failure among Individuals on Second line ART Regimen	36
5.2.2 The Mortality Rate of Individuals on Second line ART Regimen	37
5.2.3 Factors Associated with Treatment Failure among Individuals on Second line ART Regimen	39
5.3 Study Limitations.....	41
CHAPTER 6: CONCLUSIONS, RECOMMENDATIONS AND FUTURE RESEARCH	43
6.1 Conclusions.....	43
6.2 Recommendations.....	43
6.3 Future Research Questions	44
References.....	45
APPENDICES	49
Appendix I: Data Abstraction Tool.....	49
Appendix II: Request for Waiver of Informed Consent	51
Appendix III: IRB approval letter.....	52

List of Tables

Table 1	Patients' demographic characteristics
Table 2	Patients' Clinical characteristics of participants
Table 3	Mortality while on second line ART regimen
Table 4	Bivariate Analysis of treatment failure and risk factors
Table 5	Predictors of treatment failure from Multivariable Analysis

List of Figures

- Figure 1** Proportion of Viral load Suppression
- Figure 2** Mortality by age group
- Figure 3** Mortality by NRTI at ART initiation
- Figure 4** Mortality by TB status at ART initiation

Declaration

I, Sam Matekha BU/GS16/MPH/9, declare that this dissertation is my original work except where due acknowledgement has been made in partial fulfillment for the award of the degree of Master of Public Health of Busitema University. I further declare that this dissertation has not been previously presented or submitted to this University as a research project or any other institution for partial fulfillment of any qualification.

Signature:

Date.....

Dedication

This work is dedicated to my parents Mr. and Mrs. Mulongo Stephen and my dear son, Elisha Jayden Matekha.

Acknowledgement

I thank all those who in one way or other contributed and supported this work.

First and foremost, I want to thank the Almighty God for his guidance, provision and protection.

I would like to thank most sincerely my supervisors - **Prof. Jayne Byakika- Tusiime and Dr. John Peter Masette Masaba** who tirelessly gave me support and guidance right from the start of this study to the end. Your academic and professional input made it possible for this study to be done.

I wish to acknowledge with gratitude Busitema University College of health sciences and the department of Public Health in particular for the enabling academic environment that made it possible for me to complete my studies.

Thanks go to the staff of Mbale Regional Referral Hospital-ART clinic for the assistance during the data collection process.

Special appreciation goes to my dear wife Ms, Muhindo Jovia, my parents Mr. and Mrs. Mulongo, and my brothers; Dan, Rogers, Joseph and Aaron. Also my friends; Mary Nakafero, Allen, Juliet, Rose, Josephine and Colleagues of MPH the class (2016-2018) for the support and prayers through my study.

God bless you.

Dissertation Approval

This dissertation is submitted as a partial fulfillment for the award of the Masters' Degree in Public Health of Busitema University with our approval as supervisors.

1. Jayne Byakika-Tusiime, B Pharm, MSc, PhD

Associate Professor of Epidemiology

School of Health Sciences

Department of Public Health

Soroti University

P O BOX 211 Soroti

Uganda



SIGN.....

DATE...12 December 2020.....

2. Dr. John Peter Masette Masaba, MBChB, M MED (INTERN MED), FCP (ECSA)

Senior Consultant Physician/ Lecturer

Department of Internal Medicine

Faculty of Health Sciences

Busitema University

SIGN.....

DATE.....

Acronyms and Abbreviations

3TC	Lamivudine
AIDS	Acquired Immune Deficiency Syndrome
ABC	Abacavir
ARVs	Antiretrovirals
ART	Antiretroviral Therapy
AZT	Zidovudine
CD4	Cluster of Differentiation Type 4
EFV	Efavirenz
FDC	Fixed Dose Combination
HIV	Human Immunodeficiency Virus
LPV/r	Lopinavir/ritonavir
NRTI	Nucleoside Reverse Transcriptase Inhibitors
NNRTI	Non-Nucleoside Reverse Transcriptase Inhibitors
NVP	Nevirapine
OIs	Opportunistic Infections
PI	Protease Inhibitor
PMTCT	Prevention of Mother to Child Transmission of HIV/AIDS
TB	Tuberculosis
TDF	Tenofovir
UNAIDS	The Joint United Nations Program on HIV/AIDS
WHO	World Health Organization

Operational Definitions

Second-line ART The ART regimen used for treatment of individuals living with HIV who have

failed on a first-line regimen, and typically consists of a PI (Atazanavir or ritonavir) and two or NRTIs.

- Treatment Failure** A rise in plasma viral load above 1,000 copies/mL in 2 consecutive viral load measurements, the first one being done at six months after switching to second line regimen, and the second one done four months after the first viral load measurement.
- Virologic Failure** When a PLHIV on antiretroviral therapy has persistently non-suppressed viral load exceeding 1000 copies/ml (two consecutive viral load measurements within a 6-month interval, with adherence support between the two measurements) after at least 6 months of starting a new ART regimen
- Immunological Failure** A fall in CD₄ cell count to baseline (or below) or a 50% reduction from treatment peak value or presence of persistent CD₄ cell count below 100 cells/mm³
- Clinical Failure** An occurrence of new or recurrent WHO stage 4 or some stage 3 conditions in an HIV positive individual who was previously stable
- Viral load coverage** This refers to the proportion individuals on ART with a of documented viral load test in the last 12 months.

ABSTRACT

Background: ART failure is a growing public health problem and a major threat to the progress of HIV/AIDS control. In Uganda however, little is documented on treatment outcomes and their associated factors among individuals on second line ART regimen.

The rapid scale-up of ART over the past has resulted in substantial reductions in morbidity and mortality. However, as millions of people must be maintained on ART for life, individuals with ART treatment failure are increasingly encountered and the numbers are expected to rise. This could be attributed to factors such as sub-standard regimens, limited access to routine viral load monitoring, treatment interruptions, suboptimal adherence, among others. The purpose of this study was to estimate five-year cumulative treatment failure and the associated factors among individuals on second line ART regimen attending Mbale regional referral hospital.

Materials and methods: A retrospective analysis of 541 records of HIV positive individuals, switched to second line ART regimen from Jan 2012 to Dec 2017. Inferential statistics including the Chi square test and multivariable logistic regression analysis was applied to determine associations of treatment failure against of the selected demographic, laboratory and clinical factors was performed. Associations between treatment failure and the predictors was based on a p-value of less than 5% and confidence intervals level of 95%.

Results

We reviewed 541 records of individuals on second line ART regimen, of which 350 (64.7%) were female, 226 (41.8%) were married, and 197 (36.4%) were older than 35 years. The mean age at ART initiation was 30 years (SD=14.8), while the mean weight at ART initiation was 47kgs (SD=18.6), (range 4-97 kgs).

The overall proportion of treatment failure was 23%. The cumulative mortality risk for five years was 12.4% and the mortality rate was 2.5 deaths per 100 individuals per year.

The odds of developing treatment failure among individuals switched to ATV/r-based regimen were 44 % lower as compared to individuals who were switched to LPV/r ($OR_{adj}0.56$, 95% CI 0.35-0.90, $p=0.016$). while the odds of experiencing treatment failure among individuals that used AZT at ART initiation were 43% lower as compared to individuals that used a TDF based regimen at ART initiation ($OR_{adj}0.57$, 95% CI 0.33-0.98, $p=0.041$).

Conclusion:

The five year cumulative incidence of treatment failure in a cohort of 541 individuals was 23%. The type of protease inhibitor (PI) used in second line regimen and use of AZT at ART initiation were significantly associated with treatment failure. Our study also shows that the cumulative mortality risk while on second line ART regimen was 12.4% while the mortality rate was 2.5 deaths per 100 individuals per year.

Recommendations:

The Ministry of Health should consider adopting early resistance testing for persons with viral loads beyond the threshold so as to facilitate early identification of resistance and subsequent regimen switch to higher regimens.

According to the 2018 HIV prevention and treatment guidelines, third line ART regimen is only issued at the regional referral hospitals. We recommend that an alternative third-line ART regimen be availed for those individuals in district hospitals who are on a failing second-line regimen given the high level of treatment failure among individuals on 2nd line ART regimen,